Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Light helmet shows promise for chemo hair loss

NCT ID NCT05397457

Symptom relief Sponsor: Chang Gung Memorial Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a home-use helmet that shines low-level light on the scalp to help hair regrow after chemotherapy. 106 women with breast cancer who had just finished chemo used the device three times a week for four weeks. Researchers measured hair count and width, and tracked distress from hair loss. The goal was to see if this light therapy could improve hair recovery and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
low-level light therapy device (Hair Boom 69)
What this could lead to
If it works, this could offer a non-drug way to speed up hair regrowth after chemotherapy, improving quality of life.
What could go wrong
This is a small, completed trial with no phase designation. Earlier research failed to show benefit, and results may not apply to all chemotherapy types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

106 people

The number who actually took part.

Started

May 2022

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 75 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age: 20 to 75 years * Informed Consent as documented by signature. * Able to read and converse in chinese * Female * Diagnosis of breast cancer * They completed chemotherapy no more than 2 weeks * Treatment with neoadjuvant (preoperative) or adjuvant (postoperative) chemotherapy: anthracycline and taxane containing (paclitaxel or docetaxel) chemotherapy regimen. * life expectancy was at least 6 months. * Diagnosed with CIA grade 2 according to Common Terminology Criteria for Adverse Events (CTCAE) Exclusion Criteria: * scalp tumor or melanoma * having any serious mental illness or history, or taking psychotropic drugs * a medical history of dermatosis * severe liver and kidney damage * Pregnancy * Take any of the following medications for 6 months prior to initiation of the study: topical minoxidil, and spironolactone, and topical calcitriol * Receiving scalp cooling during chemotherapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm chemotherapy-induced alopecia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer Chemotherapy-induced alopecia

Contacts and locations

Locations

  • Keelung Chang Gung Memorial Hospital

    Keelung, 20401, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.